These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1131 related items for PubMed ID: 25280882

  • 1. Nanostructured lipid carriers versus microemulsions for delivery of the poorly water-soluble drug luteolin.
    Liu Y, Wang L, Zhao Y, He M, Zhang X, Niu M, Feng N.
    Int J Pharm; 2014 Dec 10; 476(1-2):169-77. PubMed ID: 25280882
    [Abstract] [Full Text] [Related]

  • 2. Binary lipids-based nanostructured lipid carriers for improved oral bioavailability of silymarin.
    Shangguan M, Lu Y, Qi J, Han J, Tian Z, Xie Y, Hu F, Yuan H, Wu W.
    J Biomater Appl; 2014 Feb 10; 28(6):887-96. PubMed ID: 24008629
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Preparation and characterization of vinpocetine loaded nanostructured lipid carriers (NLC) for improved oral bioavailability.
    Zhuang CY, Li N, Wang M, Zhang XN, Pan WS, Peng JJ, Pan YS, Tang X.
    Int J Pharm; 2010 Jul 15; 394(1-2):179-85. PubMed ID: 20471464
    [Abstract] [Full Text] [Related]

  • 6. Investigating the correlation between in vivo absorption and in vitro release of fenofibrate from lipid matrix particles in biorelevant medium.
    Borkar N, Xia D, Holm R, Gan Y, Müllertz A, Yang M, Mu H.
    Eur J Pharm Sci; 2014 Jan 23; 51():204-10. PubMed ID: 24134899
    [Abstract] [Full Text] [Related]

  • 7. Nanostructured lipid carriers used for oral delivery of oridonin: an effect of ligand modification on absorption.
    Zhou X, Zhang X, Ye Y, Zhang T, Wang H, Ma Z, Wu B.
    Int J Pharm; 2015 Feb 20; 479(2):391-8. PubMed ID: 25556104
    [Abstract] [Full Text] [Related]

  • 8. Preparation and characterization of nimodipine-loaded nanostructured lipid systems for enhanced solubility and bioavailability.
    Teng Z, Yu M, Ding Y, Zhang H, Shen Y, Jiang M, Liu P, Opoku-Damoah Y, Webster TJ, Zhou J.
    Int J Nanomedicine; 2019 Feb 20; 14():119-133. PubMed ID: 30613141
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Second generation lipid nanoparticles (NLC) as an oral drug carrier for delivery of lercanidipine hydrochloride.
    Ranpise NS, Korabu SS, Ghodake VN.
    Colloids Surf B Biointerfaces; 2014 Apr 01; 116():81-7. PubMed ID: 24445002
    [Abstract] [Full Text] [Related]

  • 11. Formulation design, characterization, and in vitro and in vivo evaluation of nanostructured lipid carriers containing a bile salt for oral delivery of gypenosides.
    Yang G, Wu F, Chen M, Jin J, Wang R, Yuan Y.
    Int J Nanomedicine; 2019 Apr 01; 14():2267-2280. PubMed ID: 31015758
    [Abstract] [Full Text] [Related]

  • 12. Formulation, Characterization, and Pharmacokinetic Studies of 6-Gingerol-Loaded Nanostructured Lipid Carriers.
    Wei Q, Yang Q, Wang Q, Sun C, Zhu Y, Niu Y, Yu J, Xu X.
    AAPS PharmSciTech; 2018 Nov 01; 19(8):3661-3669. PubMed ID: 30324361
    [Abstract] [Full Text] [Related]

  • 13. Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs.
    Dahan A, Hoffman A.
    J Control Release; 2008 Jul 02; 129(1):1-10. PubMed ID: 18499294
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Preparation and characterization of silybin-loaded nanostructured lipid carriers.
    Jia LJ, Zhang DR, Li ZY, Feng FF, Wang YC, Dai WT, Duan CX, Zhang Q.
    Drug Deliv; 2010 Jan 02; 17(1):11-8. PubMed ID: 19941406
    [Abstract] [Full Text] [Related]

  • 18. A lipid-based liquid crystalline matrix that provides sustained release and enhanced oral bioavailability for a model poorly water soluble drug in rats.
    Boyd BJ, Khoo SM, Whittaker DV, Davey G, Porter CJ.
    Int J Pharm; 2007 Aug 01; 340(1-2):52-60. PubMed ID: 17467935
    [Abstract] [Full Text] [Related]

  • 19. G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol.
    Qi R, Li YZ, Chen C, Cao YN, Yu MM, Xu L, He B, Jie X, Shen WW, Wang YN, van Dongen MA, Liu GQ, Banaszak Holl MM, Zhang Q, Ke X.
    J Control Release; 2015 Jul 28; 210():160-8. PubMed ID: 26003044
    [Abstract] [Full Text] [Related]

  • 20. Cysteine-Functionalized Nanostructured Lipid Carriers for Oral Delivery of Docetaxel: A Permeability and Pharmacokinetic Study.
    Fang G, Tang B, Chao Y, Xu H, Gou J, Zhang Y, Xu H, Tang X.
    Mol Pharm; 2015 Jul 06; 12(7):2384-95. PubMed ID: 25974386
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.